BioRestorative Therapies

brtxDISC (DiscImplantedStemCells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure. ThermoStem is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
Type
Public
HQ
Melville, US
Founded
1997
Size (employees)
6 (est)
BioRestorative Therapies was founded in 1997 and is headquartered in Melville, US

BioRestorative Therapies Office Locations

BioRestorative Therapies has an office in Melville
Melville, US (HQ)
40 Marcus Dr

BioRestorative Therapies Financials and Metrics

BioRestorative Therapies Financials

BioRestorative Therapies's revenue was reported to be $36.4 k in FY, 2016
USD

Revenue (Q3, 2017)

16 k

Market capitalization (27-Oct-2017)

19.5 m

Closing share price (27-Oct-2017)

3.4
BioRestorative Therapies's current market capitalization is $19.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.7 k416 k628.9 k36.4 k

Revenue growth, %

24662%51%(94%)

Cost of goods sold

208213.8 k261.5 k102

Gross profit

1.5 k202.2 k367.4 k36.3 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

125375175.9 k159.9 k184.9 k148.8 k96.1 k9.1 k16.2 k5 k7 k20 k16 k

Cost of goods sold

106042.4 k66.1 k76.4 k74.6 k50.9 k1071

Gross profit

115315133.6 k93.8 k108.5 k74.1 k45.2 k9.1 k16.1 k

Gross profit Margin, %

92%84%76%59%59%50%47%100%100%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

201.1 k91.8 k166.6 k31.8 k

Accounts Receivable

93.4 k6 k

Inventories

18 k1.9 k29.3 k

Current Assets

239.8 k114.3 k289.3 k61.7 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

642110.4 k59.2 k374 k145.9 k6.4 k12.8 k353.1 k516.2 k6.3 k8.9 k1.9 k

Accounts Receivable

51 k9 k16 k5 k7 k20 k16 k

Inventories

18 k17.9 k17.8 k17.4 k1.9 k2.5 k2.5 k19.6 k

Current Assets

66.3 k137.3 k95 k421.5 k180.2 k246.1 k385 k384.2 k546.2 k32.6 k38.2 k46.6 k36.3 k
    USDFY, 2014FY, 2015FY, 2016

    Net Income

    (5.6 m)(7.9 m)(8.6 m)

    Depreciation and Amortization

    96.7 k213.8 k258.4 k

    Accounts Receivable

    (93.4 k)87.4 k

    Inventories

    613(6.8 k)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (1.3 m)(1.7 m)(1.3 m)(1.1 m)(1.8 m)(1.4 m)(1.6 m)(2.5 m)(2.3 m)(1.8 m)(2.8 m)

    Accounts Receivable

    51 k9 k16 k5 k7 k16 k

    Inventories

    17.8 k17.4 k1.9 k2.5 k2.5 k19.6 k

    Accounts Payable

    893.4 k774.1 k1.3 m1.7 m2.1 m2.2 m2.1 m2 m2.3 m2.7 m
      Show all financial metrics

      BioRestorative Therapies Market Value History

      BioRestorative Therapies's Web-traffic and Trends

      BioRestorative Therapies Company Life and Culture

      You may also be interested in